+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dysmenorrhea Treatment Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 105 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4997591
The dysmenorrhea treatment market is expected to register a CAGR of 8.1% during the forecast period, 2022-2027.

COVID-19 is an unprecedented health concern that has affected millions of people physically and mentally. The pandemic has significantly impacted many people's mental health, resulting in loneliness, social isolation, financial strain, anxiety and fear of contracting the virus, and uncertainty for the future. It has been proven that periods of stress and psychological distress can affect a woman’s menstrual health. Stressors can activate the hypothalamic-pituitary-gonadal (HPG) axis and alter the neuro-modulatory cascade that drives gonadotropin, releasing hormone (GnRH) regulation, which results in an irregular menstrual cycle. The changes in menstrual cycles lead to higher episodes of dysmenorrhea, significantly impacting the market. As per the study titled "The Impact of the COVID-19 Pandemic on Women’s Reproductive Health", published in March 2021, 46% of women reported a change in their menstrual cycle, with 30% new dysmenorrhea cases, since the beginning of the pandemic. Thus, COVID-19 has impacted the dysmenorrhea treatment market significantly.

The dysmenorrhea treatment market is significantly driven by the increasing prevalence of women with dysmenorrhea and the rising R&D for the development of innovative drugs for treating menstrual cramps.

As per the study titled "Prevalence and Predictors of Dysmenorrhea, Its Effect, and Coping Mechanisms among Adolescents in Shai Osudoku District, Ghana", published in the International Journal of Gynecology & Obstetrics in May 2019, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most common gynecological problem worldwide. As per the study titled "Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain - A Practical Review", published in July 2021, various combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytics have been developed and tested, demonstrating a huge potential for future research to develop modern, effective combinations and search for new indications for the existing fixed-dose combination drugs for treating dysmenorrhea. Thus, research studies highlighting the potential of existing treatments for menstrual cramps and developing new drugs may drive the market.

However, side effects and complications associated with the long-term treatment and lack of awareness about reproductive health in women are expected to restrain the market’s growth during the forecast period.

Key Market Trends

Non-steroidal Anti-inflammatory Drugs Segment is Expected to Hold a Major Market Share in the Dysmenorrhea Treatment Market

Some of the US Food and Drug Administration (FDA)-approved NSAIDs for the treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.

According to the article published in the Women's Health Concern and British Menopause Society in December 2020, approximately 80% of dysmenorrhea women experience period pain at some stage in their lifetime. In 40% of women, period pain is accompanied by premenstrual symptoms, such as bloating, tender breasts, swollen stomach, lack of concentration, mood swings, clumsiness, and tiredness. Therefore, dysmenorrhea should be treated in its early days, which is expected to increase the usage of NSAIDs and drive the segment’s growth. As per the research article titled "Dysmenorrhea in adult females: Treatment", last updated in February 2022, NSAIDs can more effectively treat dysmenorrhea-related pain. Approximately 80 trials reported that NSAIDs were more effective than placebo for patients with primary dysmenorrhea. In September 2019, Bayer demonstrated the data showing that a single maximum non-prescription dose of Aleve (naproxen sodium) provided more pain relief over 12 hours than acetaminophen for menstrual cramps due to primary dysmenorrhea. Thus, the high efficacies of NSAIDs are readily driving the adoption rate of NSAIDs, which may boost the market’s growth.

Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also rising globally. According to an article titled "Understanding Endometriosis -- the Basics", published in July 2021, endometriosis affects an estimated 1 in 10 women during their reproductive years, which is approximately 176 million women worldwide. This factor is expected to have a significant impact on the market’s growth. Thus, due to the above-mentioned factors, the non-steroidal anti-inflammatory drugs segment is expected to contribute significantly to the market’s growth.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America is expected to hold a major market share in the dysmenorrhea treatment market. The United States is expected to contribute to this growth significantly due to the increasing incidence and prevalence of dysmenorrhea and awareness of dysmenorrhea among women.

According to the study titled "The Prevalence and Academic Impact of Dysmenorrhea in 21,573 Young Women: A Systematic Review and Meta-Analysis", published in August 2019, the prevalence of dysmenorrhea was 71.1% in the United States. Rates of dysmenorrhea were similar between students at school and university, around 75% of which is significantly high. The high prevalence of dysmenorrhea increases the demand for its treatment, thus driving the market. In addition, an increase in R&D procedures for developing new drugs and evaluating the potential of existing treatments may boost the studied market. For instance, the study titled "Continuous vs. cyclic combined hormonal contraceptives for the treatment of dysmenorrhea: a systematic review", published in January 2019, suggested that flexible/extended combined hormonal contraceptives (CHC) resulted in four fewer days of dysmenorrhea as compared to the cyclic regimen. Such research studies are expected to contribute significantly to the market’s growth.

Moreover, the launch of new products for treating the pain associated with primary and secondary dysmenorrhea is also driving the studied market. For instance, in September 2021, Myovant Sciences and Pfizer Inc. recieved the approval from US Food and Drug Administration (FDA) for the review of a supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) to manage moderate to severe pain associated with endometriosis.

Thus, due to such factors, the US dysmenorrhea treatment market is expected to grow significantly during the forecast period.

Competitive Landscape

The dysmenorrhea treatment market is competitive and consists of several major players. Some of the major players include Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase In Number of Women with Dysmenorrhea
4.2.2 Increasing Research and Development for Developing Innovative Drugs
4.3 Market Restraints
4.3.1 Side Effects and Complications Associated with Long-term Treatment
4.3.2 Lack of Awareness About Reproductive Health in Women
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.1.2 Hormonal Therapy
5.2 By Type
5.2.1 Primary Dysmenorrhea
5.2.2 Secondary Dysmenorrhea
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bayer AG
6.1.3 Abbott Laboratories
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Sanofi
6.1.6 Pfizer Inc
6.1.7 GlaxoSmithKline PLC
6.1.8 Focus Consumer Healthcare
6.1.9 Johnson & Johnson
6.1.10 Alvogen

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Bayer AG
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc
  • GlaxoSmithKline PLC
  • Focus Consumer Healthcare
  • Johnson & Johnson
  • Alvogen